About Trevena
Trevena is a publicly listed company based in Philadelphia (United States) founded in 2007. GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. Trevena has raised $203 million across 11 funding rounds from investors including NIH, HHS and Forest Laboratories. The company has 35 employees. Its focus areas include Life Sciences, Neurology, Drugs and Pain. Its competitors include Flexion Therapeutics, Tonix Pharma and Cara Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Trevena is a developer of GPCR ligand technology-based therapeutics for cardiovascular diseases and pain. It has three programs in development: TRV027, currently in Phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intravenous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.
- Headquarters Philadelphia, United States
- Employees 35
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website trevena.com
- Social X
- Legal Name Trevena, Inc.
- Annual Revenue$3.13 M (USD)as on Dec 31, 2023
- Net Profit-$40.29 M (USD)24.93as on Dec 31, 2023
- EBITDA-$34.4 M (USD)38.04as on Dec 31, 2023
- Total Equity Funding$203M (USD)
in 11 rounds
- Latest Funding Round$4M (USD), Post-IPO
Dec 2023
- InvestorsNIH
& 7 more
- Employee Count35
Funding Insights of Trevena
Trevena has successfully raised a total of $203M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $203M
- Total Rounds 11
- Last Round Post-IPO — $4M
- First Round $24M
(Mar 2008)
- Investors Count 8
Latest 10 of 11 funding rounds of Trevena with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2023 | $4M | Post-IPO | – | – | – |
| Jul 2013 | $338,162 | Grant | – | – | |
| May 2013 | $60M | Series C | – | Polaris Partners, New Enterprise Associates | – |
| May 2013 | $60M | Series C | – | – | – |
| Aug 2011 | $10M | Grant | – | – | – |
| Jul 2010 | $35M | Series B | – | – | |
| Nov 2009 | $7.65M | Grant | – | – | |
| Sep 2009 | $7.64M | Grant | – | – | |
| Sep 2009 | $7.64M | Grant | – | – | |
| Mar 2008 | $24M | Series A | – | – |
8 investors in total: 8 institutional.
Investors in Trevena
Trevena has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and Forest Laboratories.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
| hcven.com | ||||
| yedvc.co.jp | ||||
Pharmaceutical formulations are developed and marketed by Forest Laboratories. | 1954 | frx.com | New York, United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Trevena
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Trevena
12 people are tracked at Trevena (3 in leadership, 6 in board & advisors, 3 in team); the tracked headcount is 35.
| Name | Role | Group |
|---|---|---|
Carrie L. Bourdow | President & CEO | Leadership |
Robert T. Yoder | SVP, Chief Business Officer & Head of Commercial Operations | Leadership |
Angela B. | Vice President Technical Operations | Leadership |
Anne M. Phillips | Director | Board & advisors |
Barbara Yanni | Director | Board & advisors |
Jake R. Nunn | Director | Board & advisors |
Marvin H. Johnson | Director | Board & advisors |
Mark Corrigan | Director | Board & advisors |
Alex. Brown | Director | Board & advisors |
Shannon Moritz | Key Account Manager - Mountain West Region | Team |
Rapheal "Ray" Jones | Key Account Manager | Team |
Briana Hills | Key Account Manager | Team |
Complete people profiles for Trevena
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Trevena
Trevena is a publicly listed company on the OTC with ticker symbol TRVN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Jan 2014
- Listed onNASDAQ: TRVN
- Listed entityTrevena, Inc.
- Exchange sectorHealth technology
- ISINUS89532E3071
- Share price$0.07 (+450% on the day) · 2026-10-12
- Market capitalisation$57,010.00
- Volume (last session)833
Financials of Trevena
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2023 | $3.1M | -$40.3M | -$34.4M |
| 2022 | -$418,000 | -$53.7M | -$55.5M |
| 2021 | $567,000 | -$51.6M | -$51.1M |
| 2020 | $3.1M | -$29.4M | -$28.7M |
Detailed financial statements for Trevena
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Trevena
4 dated milestones of Trevena across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Trevena is founded.
- Funding First funding round of $24.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $4.0M.
Competitors of Trevena
Trevena has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Tonix Pharma and Cara Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases |
Detailed competitors of Trevena
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Trevena
The website of Trevena (trevena.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▲ 268.4% vs previous month
Top companies in Pain Management
3 companies that operate in the same segment as Trevena (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | 24 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Trevena
Complete news archive for Trevena
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Trevena
Trevena was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Trevena is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Trevena is a funded company, having raised a total of $203M across 11 funding rounds to date. The company's 1st funding round was a Series A of $24M, raised on Mar 2008.
Trevena has 35 employees.
Annual revenue of Trevena is $3.13M as on Dec 31, 2023.
Trevena is a developer of GPCR ligand technology-based therapeutics for cardiovascular diseases and pain. It has three programs in development: TRV027, currently in Phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intravenous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.
Trevena's top competitors include Flexion Therapeutics, Tonix Pharma and Cara Therapeutics.
Yes, Trevena is publicly traded on OTC under the ticker symbol TRVN.
Trevena has 8 investors. Key investors include NIH, HHS, Forest Laboratories, Polaris Partners, and NEA.